JJ ESMO 2026
Biotech

ESMO: J&J's RIPTAC is ‘best data we’ve seen’ for prostate cancer

A year after paying over $3 billion for Halda, J&J used ESMO to unveil the first data from its shiny new RIPTAC pipeline.
James Waldron Oct 25, 2026 9:45am
AstraZeneca ESMO 2026

ESMO: AZ exec insists ph. 3 ADC data ‘robust’ despite PFS miss

Oct 25, 2026 11:30am
Bristol Myers Squibb 2026

ESMO: BMS’ Massacesi hails PD-L1xVEGF data as ‘very promising’

Oct 25, 2026 7:03pm
Merck ESMO 2026

ESMO: Merck exec unruffled by ‘unfortunate’ cancer vax data leak

Oct 24, 2026 6:24am
Roche ESMO 2026

ESMO: Roche touts ‘convincing’ KRAS data after phase 3 win

Oct 25, 2026 11:30am
Eli Lilly Lilly

ESMO: Lilly ADC sees 79% ORR in competitive ovarian cancer space

Oct 24, 2026 2:30am
More News

ESMO: GSK cancer R&D chief says data ‘reinforces belief’ in mo-rez

Oct 23, 2026 6:05pm

ESMO: Boehringer builds case for late-phase rival to Imdelltra

Oct 23, 2026 10:30am

ESMO: Why Zentalis is already dreaming of launching WEE1 drug

Oct 23, 2026 10:15am

ESMO: Takeda’s $1B bet ‘absolutely’ pays off with ADC ph. 3 win

Oct 23, 2026 9:30am